Stock XENE XENON PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Real-time Estimate Cboe BZX
Other stock markets
 20:12:15 06/05/2024 BST 		5-day change 1st Jan Change
42.8 USD -2.17% Intraday chart for Xenon Pharmaceuticals Inc. +0.83% -6.46%
04-19 Xenon Pharmaceuticals Inc. Announces Board Resignations CI
03-11 Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Xenon Pharmaceuticals Inc. Announces Board Resignations
Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing
Xenon Pharmaceuticals Insider Sold Shares Worth $601,615, According to a Recent SEC Filing
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Xenon Pharmaceuticals Q4 Net Loss Widens
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Xenon Pharmaceuticals Insider Sold Shares Worth $758,983, According to a Recent SEC Filing
Sector Update: Health Care Stocks Gain Premarket Thursday
Xenon Pharmaceuticals Prices $300 Million Public Offering of Common Stock, Pre-Funded Warrants
Xenon Pharmaceuticals Launches $225 Million Public Offering
Xenon Pharmaceuticals Says Trial of Depression Drug Failed to Meet Primary Endpoint
Canada's Xenon Pharma's depression drug fails to meet main goal in study
Xenon Pharmaceuticals' depression drug fails to meet main goal in study
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-Of-Concept X-Nova Clinical Trial of Xen1101 in Major Depressive Disorder
Sector Update: Health Care Stocks Rising Late Afternoon
Sector Update: Health Care Stocks Rise Friday Afternoon
Neurocrine Reports Two Mid-Stage Trial Misses; Shares Fall
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Xenon Pharmaceuticals Announces Publication of Results from Xen1101 Phase 2B "X-Tole" Clinical Trial in Peer-Reviewed Journal Article in Jama Neurology
Xenon Pharmaceuticals Inc. Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XENE Stock
  4. News Xenon Pharmaceuticals Inc.
  5. Other languages